NCT07517250 A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
| NCT ID | NCT07517250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novartis Pharmaceuticals |
| Condition | Familial Mediterranean Fever |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2026-03-15 |
| Primary Completion | 2026-12-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2026-03-15 with a primary completion date of 2026-12-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Eligibility Criteria
Inclusion criteria: * Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD). * Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment. Exclusion criteria: • Patients Aged \<2 Years (24 Months) at Index Date.
Contact & Investigator
Novartis Pharmaceuticals
STUDY DIRECTOR
Novartis Pharmaceuticals
Frequently Asked Questions
Who can join the NCT07517250 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Familial Mediterranean Fever. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07517250 currently recruiting?
Yes, NCT07517250 is actively recruiting participants. Contact the research team at novartis.email@novartis.com for enrollment information.
Where is the NCT07517250 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT07517250 clinical trial?
NCT07517250 is sponsored by Novartis Pharmaceuticals. The principal investigator is Novartis Pharmaceuticals at Novartis Pharmaceuticals. The trial plans to enroll 160 participants.